Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 238Precursor Cell Lymphoblastic Leukemia-Lymphoma 46Recurrence 35Burkitt Lymphoma 23Neoplasms 20Neoplasms, Plasma Cell 17Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 15Immunoglobulin Light-chain Amyloidosis 13Leukemia 12Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma 10Lymphoma, Large B-Cell, Diffuse 9Lung Neoplasms 9Carcinoma, Non-Small-Cell Lung 9Prostatic Neoplasms 8Leukemia, Biphenotypic, Acute 8Neoplasm Metastasis 7Lymphoma, Non-Hodgkin 7Breast Neoplasms 7Lymphoma, B-Cell 6Smoldering Multiple Myeloma 5Nausea 5Leukemia, Myeloid, Acute 5Hodgkin Disease 5Brain Neoplasms 5Waldenstrom Macroglobulinemia 4Neoplasm, Residual 4Lymphoma, T-Cell, Peripheral 4Lymphoma, Mantle-Cell 4Amyloidosis 4

Interventions

venetoclax 1pomalidomide 1ixazomib 1daratumumab 1Dexamethasone 1Calcium Dobesilate 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Proteostasis Deficiencies × Dexamethasone × 1 year × Clear all
NCT05451771 2025-07-08

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

Columbia University

Phase 1/2 Recruiting
53 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Proteostasis Deficiencies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡